Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
[27], [29] Primary efficacy outcome Impact of treatment on gross motor function as measured via MHFMS
The most common diagnosis shifted from type 2 diabetes mellitus (T2DM) (82% in 2019) to obesity (47% in 2023)
CagriSema looks more familiar and potentially easier to contextualize because it builds on semaglutide plus amylin
Because of the complex statistical design (drug, genotype, time) and potent effect of both the drug and genotype, sometimes there was no interaction with time (main effect of drug and/or genotype)
But your employer or insurer may have negotiated different terms
US$ 26.22
US$ 24.39
US$ 23.91
